If you liked this article you might like

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot

These 5 Stocks Are Poised for Breakouts

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation